Want to see NEO full AI Analyst Report?
NEO Stock Chart & Stats
$17.37
-$0.75(-5.40%)
At close: 4:00 PM EDT
$17.37
-$0.75(-5.40%)
Day’s Range― - ―
52-Week Range$7.07 - $20.15
Previous Close$13.14
Volume1.80M
Average Volume (3M)2.18M
Market Cap
$2.11B
Enterprise Value$2.21B
Total Cash (Recent Filing)$145.54M
Total Debt (Recent Filing)$448.37M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Oct 28, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield0.75%
Share Statistics
EPS (TTM)-1.98
Shares Outstanding128,475,430
10 Day Avg. Volume2,390,261
30 Day Avg. Volume2,176,308
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.36
Price to Sales (P/S)0.41
P/FCF Ratio-13.83
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit6.72
Enterprise Value/Ebitda171.63
Forecast
1Y Price Target
$21.50Price Target Upside23.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.19
Revenue Forecast (FY)$804.90M
Bulls Say, Bears Say
Bulls Say
Clinical And NGS GrowthStrong clinical and NGS growth supports durable demand for NeoGenomics’ specialized oncology diagnostics. Rising NGS adoption, larger-panel growth, and clinical revenue expansion can deepen the company’s role in diagnosis and treatment selection while supporting sustained revenue growth.
Margin And EBITDA ExpansionImproving gross margin and adjusted EBITDA indicate that revenue growth is increasingly converting into operating leverage. Continued benefits from automation, digital pathology, instrument upgrades, and procurement could support more durable profitability as testing volumes scale.
Manageable Leverage And LiquidityA substantial equity base, moderate leverage, and meaningful cash balance provide financial support during the transition toward profitability. This balance-sheet position gives NeoGenomics flexibility to fund laboratory investment and commercial expansion while absorbing operating volatility.
Bears Say
Persistent Unprofitability And Negative Free Cash FlowNeoGenomics has not yet demonstrated consistent GAAP profitability or positive free cash flow after investment needs. Continued losses constrain internally generated capital, while negative cash conversion could limit flexibility if margin improvement or revenue growth falls short of expectations.
Pharma And Nonclinical Revenue WeaknessWeakness in the pharma and nonclinical businesses creates a meaningful offset to clinical growth and reduces near-term revenue diversification. Although bookings reached a high, delayed pull-through means recovery depends on converting those bookings into recognized revenue.
Reimbursement-dependent RaDaR ST ScalingRaDaR ST has strategic potential but currently contributes only modest revenue and requires further reimbursement support to scale commercially. Pending coverage decisions introduce uncertainty around adoption, timing, and the pace at which this newer diagnostic offering can become material.
NeoGenomics News
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $7.07 and its highest was $20.15 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $2.11B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Oct 28, 2026 which is in 8 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Jul 28, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.034 by $0.016.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics pays a Notavailable dividend of $0.4 which represents an annual dividend yield of 0.75%. See more information on NeoGenomics dividends here
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.06.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,475,430 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.05 in its last earnings report, beating expectations of $0.034. Following the earnings report the stock price went up 13.955%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (23.78% Upside)
$21.50 (23.78% Upside)
Blogger Sentiment
Bullish
NEO Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 885.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $321.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.38%
12-Months-Change
Fundamentals
Return on Equity
-6.31%
Trailing 12-Months
Asset Growth
-2.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NeoGenomics
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NEO Company Deck
NEO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid commercial and margin momentum driven by strong NGS and clinical performance, operational efficiencies from the Lab of the Future program, and constructive guidance and capital structure actions. Headwinds were concentrated in the smaller nonclinical/pharma segment (notably a 26% decline in Pharma revenue) and timing-sensitive items (reimbursement for RaDaR ST, a DOJ settlement impact, and a tougher Q3 comp from exiting a high-volume low-value contract). Overall, the company demonstrated durable clinical growth, margin expansion and strengthened liquidity while acknowledging discrete near-term challenges that management plans to address.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$21.50
▲(23.78% Upside)
Technical Analysis
Ownership Overview
0.83% Insiders
26.87% Mutual Funds
0.08% Other Institutional Investors
38.99% Public Companies and
Individual Investors